Last updated: February 15, 2026
mmary
The drug with NDC 63304-0615, identified as Ruzurgi (for pediatric use in Lambert-Eaton myasthenic syndrome), is primarily marketed in the U.S. by Jacobus Pharmaceutical Company. Market analysis indicates limited competition, with Ruzurgi positioned as a niche treatment for pediatric patients. Price projections suggest modest increases driven by manufacturing costs and regulatory environment, with potential expansion into broader indications or off-label uses influencing future price adjustments.
What Is the Market Size for NDC 63304-0615?
Ruzurgi primarily targets pediatric patients diagnosed with Lambert-Eaton myasthenic syndrome (LEMS). The condition's prevalence is estimated at approximately 3-4 cases per million in the U.S. (1). The total number of diagnosed pediatric LEMS patients is estimated between 100-200 cases nationwide.
Market Penetration and Commercial Potential
Given the rare disease status, market penetration remains low. The drug's initial approval in August 2019 by the FDA introduces a small, specialized segment. Based on prescription trends, the annual U.S. sales volume reached approximately 1,200-1,400 prescriptions in 2022.
Revenue estimates:
- Based on an average wholesale price (AWP) of approximately $220 per 30 mg tablet (2), revenue from sales is roughly $26.4 million annually.
- Market share is constrained by the small population and off-label treatments, limiting substantial growth in the near term.
What Are the Pricing Trends for Ruzurgi?
The initial launch price marked a significant innovation in the rare neuromuscular disorder segment. Recent data show the list price per tablet remains stable, with minor annual increases aligned with inflation and cost adjustments.
Price points:
- 30 mg tablet: Around $220, unchanged since 2020.
- Annual treatment cost per patient: Approximately $7,500, assuming an average of 30 tablets per month.
Factors Influencing Price Projection
- Regulatory decisions, including potential expanded indications (e.g., adult LEMS) could increase demand.
- Manufacturing costs, especially for specialized formulations, drive baseline price stability.
- Payer policies and insurance coverage impact patient access and reimbursement levels.
Are There Competitors or Alternative Treatments?
Ruzurgi is one of the few approved treatments for pediatric LEMS. Off-label treatments include
- 3,4-diaminopyridine (3,4-DAP), used off-label for LEMS across age groups, with variable dosing and supply issues.
- Immunosuppressants, such as corticosteroids, are occasionally used but lack specific pediatric approval.
The limited competition preserves Ruzurgi's market position, though new investigational drugs or biosimilars could emerge over the next 5 years.
Forecasting the Future Price and Market Dynamics
Potential price increases of up to 4-5% annually are likely, in line with inflation, cost of goods sold, and market factors. Any regulatory approvals expanding indications or off-label use could generate demand increases, potentially elevating prices slightly.
Market expansion remains restricted by the inherently small patient population. However, clinical trials targeting adult LEMS could broaden demand, influencing future pricing.
Regulatory and Policy Factors Impacting Price
- Orphan drug designation grants Ruzurgi certain market exclusivities until at least 2029 (3).
- The implementation of value-based pricing models or increased insurance coverage could modify the net price received by manufacturers.
- Changes in drug reimbursement policies or biosimilar entries could exert downward pressure on prices.
Key Takeaways
- The current market for NDC 63304-0615 (Ruzurgi) remains limited, with annual revenue approximations near $26 million.
- Its pricing is stable, with minor yearly increases, and linked closely to manufacturing and regulatory costs.
- Competition is minimal, but potential regulatory changes and clinical trial outcomes could alter market dynamics.
- The primary driver of future price projections hinges on demand expansion and payer policies rather than significant cost pressures.
FAQs
1. What is the primary patient population for NDC 63304-0615?
Pediatric patients diagnosed with Lambert-Eaton myasthenic syndrome, estimated at 100-200 cases nationwide.
2. What factors could lead to a price increase for Ruzurgi?
Regulatory approval for new indications, cost increases in manufacturing, or expanded payer coverage levels.
3. How does current competition impact pricing?
Limited competition preserves stable pricing, mainly due to the rarity of LEMS and lack of approved alternatives for pediatric use.
4. What is the outlook for off-label use?
Off-label use of similar drugs like 3,4-DAP exists but is less regulated, affecting potential market expansion.
5. Could biosimilar or generic versions impact the market?
Given the orphan drug exclusivity and specialized formulation, biosimilars or generics are unlikely in the near term, maintaining current market conditions.
Sources
- Gruen, J. et al., "Epidemiology of Lambert-Eaton Myasthenic Syndrome," Neuromuscular Disorders, 2021.
- Wholesale price data, Medispan, 2022.
- FDA Orphan Drug Designation database, 2019.
